Abbott – Cafepharma Message Boards
Nutritional
Safety and Efficacy Rates in Patients with Challenging Anatomy Consistent with Superior Results from Randomized Clinical Trials BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at EuroPCR from an international, post-approval, single-arm study show that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated low rates of repeat .Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac . (redOrbit)
- New data to be presented on Abbott's market-leading XIENCE V(R) stent - Educational information available on XIENCE PRIME(TM), Abbott's next-generation drug eluting stent in development BARCELONA, Spain, May 18 /PRNewswire-FirstCall/ -- ...